We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Rapid Antigenic Diagnostic Test Validated for Ebola Virus Disease

By LabMedica International staff writers
Posted on 13 Feb 2020
Print article
Image: The FUJI DRI-CHEM IMMUNO AG1 analyzer (Photo courtesy of FUJI FILM).
Image: The FUJI DRI-CHEM IMMUNO AG1 analyzer (Photo courtesy of FUJI FILM).
Hemorrhagic fever outbreaks are difficult to diagnose and control in part because of a lack of low-cost and easily accessible diagnostic structures in countries where etiologic agents are present. Initial clinical symptoms are common and shared with other endemic diseases such as malaria or typhoid fever.

Current molecular diagnostic methods such as polymerase chain reaction require trained personnel and laboratory infrastructure, hindering diagnostics at the point of need, particularly in outbreak settings. Therefore, rapid diagnostic tests such as lateral flow can be broadly deployed and are typically well-suited to rapidly diagnose hemorrhagic fever viruses, such as Ebola virus (EBOV).

Scientists working for BIOASTER (Lyon, France) and their international colleagues developed and characterized an immunoassay test based on immunochromatography coupled to silver amplification technology to detect the secreted glycoprotein of EBOV. The glycoprotein is among the first viral proteins to be detected in blood. The investigators obtained blood samples from European volunteers, 70 healthy African volunteers (54 men and 16 women), and from Ebola infected patients used in the work were frozen leftovers from clinical study performed during 2014 outbreak.

The team developed Ebola non-structural secreted glycoproteins (sGP) Detection Kit with silver amplification immunochromatography technology. An anti-mouse immunoglobulin and EE8 antibody were immobilized onto nitrocellulose membranes to generate the control and test lines, respectively. A reagent pad containing XC2 monoclonal antibody (mAb) conjugated with colloidal gold (British Biocell International, Cardiff, UK) was placed between the sample application point and test line. The test strip was then placed in a FUJI DRI-CHEM IMMUNO AG cartridge (FUJIFILM, Tokyo, Japan). Results express as delta OD values were calculated by FUJI DRI-CHEM IMMUNO AG1 analyzer based on OD values before and after silver amplification reaction.

The scientists assessed Ebola sGP Detection Kit clinical sensitivity and specificity with plasma samples from infected individuals. Patients were included in the cohort based on quantitative Reverse Transcription Polymerase Reaction Chain (RT-qPCR) test positivity, i.e. when Ct values were inferior to 34 cycles. Out of 21 patients diagnosed by RT-qPCR, 18 patients were positive with the Ebola sGP detection Kit test, giving a sensitivity of 85.7%. Out of the three patients not detected by Ebola sGP Detection Kit, all are close to the RT-qPCR detection limits with Ct values of 31, 32 and 33 cycles. Positive and negative predicting value were 100% and 97,5% respectively, but further work is required to definitively define the clinical performances of the Ebola sGP detection Kit.

The authors concluded that the LFA developed together with the easy-to-use reader equipment gave highly specific and sensitive results that could be implemented in low-resource laboratories to help monitoring and diagnosing Zaire ebolavirus (ZEBOV) in countries where outbreaks could start. The study was published on January 20, 2020 in the journal PLOS Neglected Tropical Diseases.

Related Links:
BIOASTER
British Biocell International
FUJIFILM


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.